GlassScriptPhysician profile
Lee T Chan
NPI 1992728414
$19,982.73
in general payments reported to CMS, 2019-2025
34 companies · $2,557 in 2025
The $2,557 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $2,522 · 2021: $3,407 · 2022: $3,393 · 2023: $3,131 · 2024: $3,105 · 2025: $2,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,763 · Education: $30.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,762.97 |
| Education | $30.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,903.88 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,939.04 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $1,903.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,666.07 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,376.98 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,255.55 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $995.80 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Gilead Sciences, INC. | $937.07 | 2020-2025 | |
| Pfizer INC. | $814.94 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $791.72 | 2019-2025 | Farxiga, Breztri |
| Janssen Biotech, INC. | $742.82 | 2022-2025 | Tremfya |
| Abbvie INC. | $721.28 | 2021-2025 | Vraylar |
| Amarin Pharma, INC. | $629.91 | 2019-2022 | |
| Glaxosmithkline, LLC. | $578.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Radius Health, INC. | $566.81 | 2019-2025 | Tymlos |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $390.96 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $274.71 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $260.47 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $207.61 | 2019-2025 | Zoryve |
| Ironwood Pharmaceuticals, INC | $197.28 | 2019-2024 | Linzess |
| Biogen, INC. | $152.62 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $127.06 | 2020-2021 | |
| Sanofi Pasteur INC. | $116.13 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $87.63 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $74.27 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $64.02 | 2021 | |
| Allergan, INC. | $47.04 | 2019-2020 | |
| Exact Sciences Corporation | $28.93 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $28.88 | 2023 | Aptima |
| Vanda Pharmaceuticals INC. | $25.50 | 2020 | |
| Avanir Pharmaceuticals, INC. | $24.40 | 2019 | |
| Hikma Pharmaceuticals USA | $20.00 | 2019 | |
| Ibsa Pharma INC. | $18.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.